RT @Myeloma_Doc: #Myeloma Paper of the Day: Retrospective study of Isa-pom-dex in relapsed/refractory AL #amyloidosis finds overall heme re….

RT @sama: I’m not big on identities, but I am extremely proud to be American. This is true every day, but especially today—I firmly believe….

Reading this @SubstackInc article by @Rfonsi1 inspired me to look at the MRD-negativity rate of all contemporary regimens in the Len-refractory space (~1-3 prior lines). As we can see, cilta-cel way ahead of everything else! Also, most trials don't even report MRD-neg rates at

RT @BloodCancerTalk: Our new episode on overview of Menin Inhibitors in AML with @Doctor_E_Stein from @MSKCancerCenter just dropped! We had….

RT @ContactoAmeh: Sesión académica extraordinaria: "Mieloma múltiple en recaída" 🧬🧫. Coord. Dr. @dgomezalmaguer 👨‍⚕️. Expertos:.Dra. Aline….

Excellent @NewYorker essay by @DrSidMukherjee on pitfalls of screening tests: .Findings more cancers ≠ saving lives!.Lead-time and length-time bias create illusions of benefit!.Even promising technologies like @GrailBio must prove survival benefit in RCTs before @US_FDA approval.

RT @NicoGagelmann: I know you say Impact Factor is not everything, but we all know it is something!. Here are top hematology journals by pr….

RT @vhugo8762: Andromeda data after 5 years, very reassuring! #EHA2025

RT @DavidSteensma: So far, every single abstract I’ve listened to at #EHA25 reporting a clinical trial has claimed the study drug was “well….

RT @Eddie_Cliff: Dr @AjaiChari "when I am introducing a BCMA-BsAb to a clinician who hasn't given one before, I liken it to the infection r….

RT @VincentRK: @TMSchmidtMD @psharmaMD @BijoyTelivala @OncBrothers @RahulBanerjeeMD @HadidiSamer @rajshekharucms #1. You don’t need sequenc….

RT @MayoClinicNeph: The Mayo MGRS Prediction Tool calculates the risk of finding monoclonal gammopathy of renal significance in a kidney bi….

To sum up, exciting data overall, with a hint of emerging plateau in PFS curve beyond 40 months! Two things to watch out for in longer follow-up of this trial and cilta-cel RCTs in earlier lines ➡️Risk of hematologic SPMs and CTTLN!.

Now, safety!.Total hematologic SPMs: 10 patients (10.3%)! .Now new cases of Parkinsonism since the 2-year follow-up report (~6%) . I am curious to see the cumulative hematologic SPM risk in long-term follow-up of BCMA BsAbs, and more mature data on CARTITUDE-4! . Also, no cases.

Can we call it "Cure"? .On a closer look of the PFS K/M curve, a plateau seems to be emerging beyond month #40 post-infusion! . Will this plateau sustain on longer follow-up?

Topline PFS results: ~1/3rd alive and progression-free at 5 years! Overall, this is very impressive in a triple-class refractory population. This efficacy benchmark will be helpful, as new BCMA CAR Ts being tested, and we will have long-term follow up from those products soon!

Median follow-up ~5 years! .I am no expert in censoring unlike @Timothee_MD, but looking at the PFS K/M curve, its reassuring that most censoring after 60 months, as expected given the follow-up time (Not much early censoring 👍)!.

Ruminating over all the exciting #MultipleMyeloma data from #ASCO25, here are some of my thoughts on the long-term follow-up of CARTITUDE-1 trial (now published in @JCO_ASCO).

Glad to see this paper in @BloodAdvances! 2-year risk of progression to MM in 20/2/20 high-risk no longer ~50% with modern active surveillance! Very few morbid progressions (SLiM, anemia and asymptomatic imaging-detected lesions drives most of the progressions). More data to.

RT @HadidiSamer: #mmsm #IMWG25 . Nice publication shared by @thanosdimop @BloodAdvances . n=427 patients after 2014 with patterns of diseas….